白细胞介素-17在银屑病和银屑病关节炎中的致病作用。
Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
作者信息
Chiricozzi A
机构信息
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; Laboratory for Investigative Dermatology, The Rockefeller University, New York, USA.
出版信息
Actas Dermosifiliogr. 2014 Oct;105 Suppl 1:9-20. doi: 10.1016/S0001-7310(14)70014-6.
Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics. Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.
银屑病是一种慢性炎症性皮肤病，由多种免疫细胞类型和组织细胞产生的细胞因子和趋化因子复杂网络所导致。新出现的证据表明，白细胞介素-17（IL-17）和白细胞介素-23/T17轴在银屑病发病机制中起核心作用，这为使用IL-17阻断剂作为治疗方法提供了理论依据。三种靶向IL-17信号传导的药物正在进行III期临床试验研究：司库奇尤单抗和依奇珠单抗（IL-17中和剂），以及布罗达单抗（IL-17受体拮抗剂）。所有抗IL-17药物的初步结果都非常有前景，使人们对这类药物作为治疗银屑病的新有效治疗方法抱有合理期望。
Zotero 插件